



## Clinical Experience with NexoBrid® Burns and Other Traumatic Injuries

April 11, 2026



Symposium on Advanced  
Wound Care

# NexoBrid<sup>®</sup>

(8.8% concentration)

Early, effective and selective non-surgical eschar removal for severe burns

**Indication:** Eschar removal in deep partial and full-thickness thermal burns in adults and pediatric patients

**Target users:** Hospitalized patients

**Treatment:** Single application for 4 hours

**Proof of concept:** Blast Injuries, Friction Burns (Road rash)

**Planned studies:** Retrospective and prospective studies in blast injuries and friction burns




Clinically Validated & commercialized


Approved in 40+ countries including US, EU, JP >16,000+ patients treated to date

# NexoBrid - Phase 3 Demonstrated Superiority over SOC<sup>1</sup>


### Incidence of complete eschar removal



### Time to complete eschar removal (days)



### Incidence of surgical eschar removal



### Blood loss



Safe and well-tolerated

Improved scarring and comparable wound closure

Consistent across various studies<sup>2</sup> and post-marketing data<sup>3,4</sup>

# NexoBrid Selectivity



# NexoBrid - Burns

**Patient:** 18-years-old male

**Clinical presentation:** Full thickness flame burn

**Treatment:** Debridement with NexoBrid; allograft placed immediately and removed on Day 13



Pre-NXB



Post-NXB



Post-Soaking



12 Months

# NexoBrid - Blast Injuries

**Patient:** 19-years-old male

**Clinical presentation:** SPT and DPT cutaneous secondary blast injury

**Treatment:** Debridement with NexoBrid



Pre-NXB



Post-NXB

# NexoBrid - Complex Trauma

**Patient:** 20-year-old male

**Clinical presentation:** Complex Trauma - combined lacerations, fractures, shrapnel and deep burns

**Treatment:** Debridement with NexoBrid



Pre-NXB



Post-NXB

# NexoBrid - Road Rash

**Patient:** Pediatric female

**Clinical presentation:** Friction burn over medial aspect of left leg

**Treatment:** Debridement with NexoBrid




Pre-NXB



ImageJ - Software



Post-NXB




ImageJ - Software

# New York 2001

After the World Trade Center attack, New York City's Cornell Burn Center treated only 14 burn victims.

The clinical demands overwhelmed the facility's surgical capacity for more than two months, requiring an additional 64 team members.

*- Dr. Palmer Bessy 2012, FDA public workshop burn MCMs*



# Switzerland 2026

A large, intense fire with bright orange and yellow flames. In the foreground, a dark metal structure, possibly a bridge or a walkway, is silhouetted against the fire. The fire appears to be consuming a large area, with thick smoke rising from the top.

Within hours of the Crans-Montana fire, Switzerland's specialized burn units were overwhelmed, requiring international evacuation of severely burned patients and emergency use of NexoBrid.

119 burn casualties.

80 of which treated with NexoBrid.

– Swiss hospital reports, 2026

# National Stockpiling and Preparedness Programs

U.S. BARDA	International WHO BMCI framework	Europe National consensus documents
 <p><b>Increasing Preparedness by Improving Burn Care</b></p> <div data-bbox="147 499 784 614" style="border: 2px solid red; padding: 5px;"> <p><b>NEXOBRID™</b> Minimize Surgical Debridement – Enzymatic @bedside</p>  </div> <div data-bbox="203 621 751 714"> <p><b>RECELL®</b> Use Intra Donor Tissue – Autograft Sparing</p>  </div> <div data-bbox="203 721 751 828"> <p><b>STRATAGRAFT™</b> Avoid need for donor tissue – Use Skin substitute</p>  </div>	<p>Recommendations for burns care in mass casualty incidents: WHO Emergency Medical Teams Technical Working Group on Burns (WHO TWGB) 2017-2020</p> <p>Amy Hughes<sup>a, b</sup> Takayuki Ogura<sup>a, c</sup> Tom Potokar<sup>a, f</sup></p>  <p><b>World Health Organization</b></p> <p><b>Standards and recommendations for burns care in mass casualty incidents</b></p>	<p><b>Bromelain-based enzymatic burn debridement: Spanish multidisciplinary consensus</b></p> <p>Jordi Serracanta<sup>a</sup> · Jacinto Baena<sup>a</sup> · José R. Martínez-Mendez<sup>a</sup> · Manuel Sánchez-Sánchez<sup>d</sup> · Eugenia López-Suso<sup>d</sup> · Rita Galeiras<sup>a</sup> · María Dolores Pérez-del-Caz<sup>e</sup> · Carmen Vivo-Benlloch<sup>e</sup> · Enrique Monclus-Fuertes<sup>f</sup> · Jacobo Casaldueiro-Viú<sup>g</sup> · Patricia María Dolores Rincon-Ferrari<sup>h</sup></p> <p><b>Italian recommendations on enzymatic debridement in burn surgery</b></p> <p>Stefano Maggio<sup>b</sup>, Lucia Orlandi<sup>d</sup>, Roberto D'Alessio<sup>g</sup>, Alessandro...</p> <p><b>A Questionnaire-Based Study to Obtain a Consensus from 5 Polish Burns Centers on Eschar Removal by Bromelain-Based Enzymatic Debridement in 2020 Update</b></p> <p><a href="https://doi.org/10.31925/farmacina.2021.4.22">https://doi.org/10.31925/farmacina.2021.4.22</a></p> <p><b>A NEW BROMELAIN-ENRICHED PROTEOLYTIC ENZYMES CONCENTRATE TREATMENT IN PATIENTS WITH EXTENSIVE BURNS: ROMANIAN CONSENSUS</b></p> <p>SILVIU ADRIAN MARINESCU<sup>1</sup>, BOTNARU<sup>2</sup>, M...</p> <p><b>Eschar removal by bromelain based enzymatic debridement (Nexobrid®) in burns: European consensus guidelines update</b></p> <p>Christoph Hirche<sup>a</sup>, Stian Kreken Almeland<sup>b</sup>, Baljit Dheansa<sup>c</sup>, Paul Fuchs<sup>d</sup>, Maurizio Governa<sup>e</sup>, Henk Hoeksma<sup>f</sup>, Tomasz Korzeniowski<sup>g</sup>, David B. Lumenta<sup>h</sup>, Silviu Marinescu<sup>i</sup>, José Ramón Martínez-Mendez<sup>j</sup>, Jan A. Plock<sup>k</sup>, Frank Sander<sup>l</sup>, Benjamin Ziegler<sup>m</sup>, Ulrich Kneser<sup>n</sup></p>

# Summary

## **BBD (Bromelain Based Debridement):**

Precisely removes eschar while preserving viable tissue for optimal outcomes

## **Clinically proven for acute wounds:**

- Burns
- Blast injuries
- Friction injuries/Road rash
- Complex trauma

## **Endorsed by international consensus guidelines**

- Recognized as standard of care for eschar removal
- Included in BMCI preparedness protocols